Ivax Corporation has received a final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for clarithromycin tablets USP, 250 mg and 500 mg. This product will be sold through the company's wholly owned subsidiary, Ivax Pharmaceuticals, Inc.

Clarithromycin is the generic equivalent of Biaxin Filmtab, which is marketed by Abbott Laboratories for the treatment of mild to moderate infections. According to IMS data, US sales of clarithromycin tablets, 250 and 500 mg were $196.9 million for the twelve-months ending March 2005.

Ivax Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the US and internationally.